Acute Infectious Encephalitis and Myelitis in Guadeloupe by New Generation Sequencing

Recruiting now

Conditions studied: Acute Encephalitis, Acute Myelitis

In brief

: Encephalitis or myelitis is defined as the inflammatory or infectious involvement of the cerebral parenchyma or spinal cord. When an infectious origin is suspected, the germ is not always identified. Next-generation sequencing could be used to correct an etiological diagnosis of these severe conditions in Guadeloupe. The rate of cases for which the infectious agent is not identified encourages continued diagnostic efforts, with the objective of identifying new pathogens or emerging pathogens, some of which may be more specific in the tropics.

Key facts

Study ID

NCT07251049

Run by

Centre Hospitalier Universitaire de la Guadeloupe

People needed

100

Starts

2023-11-16

Expected to finish

2028-11-16

Last updated by the study team

2025-11-26

Who can join

Age: 0 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• We selected the following eligibility criteria for patients with acute encephalitis:
• Patient of at least 28 days of life
• With acute onset of symptoms for more than 24 hours
• A major criterion among the following:
• a disorder of consciousness or alertness
• memory disorder
• lethargy
• modification of personal or behavioral disorder, irritability
• confusion, disorientation in time or space
• At least two of the following minor criteria:
• temperature above 38 ° C
• new onset focal neurological deficit
• epileptic crisis
• biological abnormality of CSF (≥ 5 Leukocytes / mm3, protein ≥ 0.40 g / L)
• partial or general epileptic seizure (s) not attributable to pre-existing epileptic disease and / or a recent focal neurological symptom
• brain imaging suggestive of encephalitis, with EEG abnormalities suggestive of encephalitis
• And absence of alternative diagnosis (intoxication, metabolic encephalopathy)
• Persons affiliated or benefiting from a social security scheme;
• Having given free, informed, written and signed consent by the patient or his legal representative (no later than the day of inclusion and prior to any review required by the research);
• Eligibility criteria for Acute Transverse Myelitis Patients:
• Patient of at least 28 days of life
• Acute onset of symptoms for more than 24 hours
• Medullary focal abnormality, responsible for motor, sensory or autonomic symptoms
• contrast enhancement on bone marrow MRI and / or abnormal CSF (≥ 5GB / mm3, protein uptake ≥ 0.40 g / L)
• Evolution between nadir and maximum symptoms, less than 4 weeks

You may not qualify if…

• Primary vasculitis of the central nervous system or a documented specific impairment in an autoimmune condition
• Cerebral thrombophlebitis if not associated with encephalitis
• Meningitis without clinical or paraclinical argument for cerebral parenchymal involvement
• Pyogenic abscess
• Cerebral or spinal abscess
• Tumoral or hematological pathology of the central nervous system
• Toxic or metabolic encephalopathy
• Transverse myelitis with vascular or traumatic origin
• Known chronic infection with HTLV virus

Where it is running

• Centre Hospitalier Universitaire de la Guadeloupe — Pointe-à-Pitre, Guadeloupe, Guadeloupe (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.